Fenofibrate: Difference between revisions
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (5 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption=' | <StructureSection load='' size='340' side='right' caption='Fenofibrate' scene='97/977745/Cv/1'> | ||
Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref> It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces to the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref><ref name="a3">PMID:20228404</ref><ref name="a4">PMID:31562117</ref> See also [https://en.wikipedia.org/wiki/Fenofibrate]. | Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref> It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces to the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.<ref name="a2">"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.</ref><ref name="a3">PMID:20228404</ref><ref name="a4">PMID:31562117</ref> See also [https://en.wikipedia.org/wiki/Fenofibrate]. | ||
In summary, enhanced catabolism of triglyceride-rich particles and reduced secretion of VLDL underlie the hypotriglyceridemic effect of fibrates, whereas their effect on HDL metabolism is associated with changes in HDL apolipoprotein expression.<ref name="a28">PMID:9808609</ref> | |||
Fenofibrate is a fibrate derivative, a prodrug comprising fenofibric acid linked to an isopropyl ester. It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII, which increases lipolysis and elimination of triglyceride-rich particles from plasma.<ref name="a28">PMID:9808609</ref> See [[Peroxisome Proliferator-Activated Receptors]] and [[Lipoprotein Lipase (LPL) complexed with GPIHBP1]]. | |||
PPARα also increases apoproteins AI and AII, reduces VLDL- and LDL-containing apoprotein B, and increases HDL-containing apoprotein AI and AII. | |||
<scene name='97/977745/Cv/2'>PPARalpha ligand binding domain-fenofibric acid co-crystals</scene> ([[6lx4]]). | <scene name='97/977745/Cv/2'>PPARalpha ligand binding domain-fenofibric acid co-crystals</scene> ([[6lx4]]). | ||
<scene name='97/977745/First_binding_site/1'>First fenofibric acid binding site</scene>. Water molecules are shown as red spheres. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||